软组织肉瘤免疫治疗的潜力。
Potential for immunotherapy in soft tissue sarcoma.
作者信息
Tseng William W, Somaiah Neeta, Engleman Edgar G
机构信息
a Section of Surgical Oncology; Division of Upper GI/General Surgery; Department of Surgery ; University of Southern California; Keck School of Medicine ; Los Angeles , CA USA.
出版信息
Hum Vaccin Immunother. 2014;10(11):3117-24. doi: 10.4161/21645515.2014.983003.
Abstract
Soft tissue sarcomas (STS) are rare, heterogeneous tumors of mesenchymal origin. Despite optimal treatment, a large proportion of patients will develop recurrent and metastatic disease. For these patients, current treatment options are quite limited. Significant progress has been made recently in the use of immunotherapy for the treatment of other solid tumors (e.g. prostate cancer, melanoma). There is a strong rationale for immunotherapy in STS, based on an understanding of disease biology. For example, STS frequently have chromosomal translocations which result in unique fusion proteins and specific subtypes have been shown to express cancer testis antigens. In this review, we discuss the current status of immunotherapy in STS, including data from human studies with cancer vaccines, adoptive cell therapy, and immune checkpoint blockade. Further research into STS immunology is needed to help design logical, subtype-specific immunotherapeutic strategies.
摘要
软组织肉瘤（STS）是起源于间充质的罕见异质性肿瘤。尽管进行了最佳治疗，仍有很大一部分患者会出现复发和转移性疾病。对于这些患者，目前的治疗选择非常有限。最近在免疫疗法治疗其他实体瘤（如前列腺癌、黑色素瘤）方面取得了重大进展。基于对疾病生物学的理解，STS采用免疫疗法有充分的理论依据。例如，STS经常发生染色体易位，导致独特的融合蛋白，并且已证明特定亚型表达癌胚抗原。在本综述中，我们讨论了STS免疫疗法的现状，包括来自癌症疫苗、过继性细胞疗法和免疫检查点阻断的人体研究数据。需要对STS免疫学进行进一步研究，以帮助设计合理的、亚型特异性的免疫治疗策略。
相似文献
1
Potential for immunotherapy in soft tissue sarcoma.软组织肉瘤免疫治疗的潜力。
Hum Vaccin Immunother. 2014;10(11):3117-24. doi: 10.4161/21645515.2014.983003.
2
Immunotherapy in Sarcoma: Future Horizons.肉瘤的免疫疗法：未来展望
Curr Oncol Rep. 2015 Nov;17(11):52. doi: 10.1007/s11912-015-0476-7.
3
Immunotherapy: A New (and Old) Approach to Treatment of Soft Tissue and Bone Sarcomas.免疫疗法：软组织和骨肉瘤治疗的新（和旧）方法。
Oncologist. 2018 Jan;23(1):71-83. doi: 10.1634/theoncologist.2016-0025. Epub 2017 Sep 21.
4
Therapeutic potential of dendritic cell vaccines in sarcoma of the extremities.树突状细胞疫苗在四肢肉瘤中的治疗潜力。
Expert Rev Anticancer Ther. 2009 Aug;9(8):1065-71. doi: 10.1586/era.09.78.
5
Immunotherapy in soft-tissue sarcoma.软组织肉瘤的免疫治疗。
Curr Oncol. 2020 Feb;27(Suppl 1):17-23. doi: 10.3747/co.27.5407. Epub 2020 Feb 1.
6
Immunotherapy for Soft Tissue Sarcoma: Tomorrow Is Only a Day Away.软组织肉瘤的免疫疗法：明日已近在咫尺。
Am Soc Clin Oncol Educ Book. 2016;35:281-90. doi: 10.1200/EDBK_157439.
7
Soft tissue sarcoma as a model disease to examine cancer immunotherapy.软组织肉瘤作为一种用于研究癌症免疫疗法的模型疾病。
Curr Opin Oncol. 2001 Jul;13(4):270-4. doi: 10.1097/00001622-200107000-00010.
8
Integrated Expression Profiles Analysis Reveals Correlations Between the IL-33/ST2 Axis and CD8 T Cells, Regulatory T Cells, and Myeloid-Derived Suppressor Cells in Soft Tissue Sarcoma.综合表达谱分析揭示了白细胞介素-33/ST2 轴与软组织肉瘤中 CD8 T 细胞、调节性 T 细胞和髓源抑制细胞的相关性。
Front Immunol. 2018 May 29;9:1179. doi: 10.3389/fimmu.2018.01179. eCollection 2018.
9
Cellular immunotherapy for soft tissue sarcomas.软组织肉瘤的细胞免疫治疗。
Immunotherapy. 2012 Mar;4(3):283-90. doi: 10.2217/imt.12.3.
10
Immunotherapy for sarcomas.肉瘤的免疫治疗。
Jpn J Clin Oncol. 2021 Apr 1;51(4):523-537. doi: 10.1093/jjco/hyab005.
引用本文的文献
1
Immune monitoring of trabectedin therapy in refractory soft tissue sarcoma patients - the IMMUNYON study.曲贝替定治疗难治性软组织肉瘤患者的免疫监测——IMMUNYON研究。
Front Immunol. 2025 Feb 11;16:1516793. doi: 10.3389/fimmu.2025.1516793. eCollection 2025.
2
Identification of hub genes correlated with tumor-associated M1-like macrophage infiltration in soft tissue sarcomas.软组织肉瘤中与肿瘤相关的M1样巨噬细胞浸润相关的枢纽基因的鉴定。
Front Genet. 2022 Dec 6;13:999966. doi: 10.3389/fgene.2022.999966. eCollection 2022.
3
A Newly Established Cuproptosis-Associated Long Non-Coding RNA Signature for Predicting Prognosis and Indicating Immune Microenvironment Features in Soft Tissue Sarcoma.一种新建立的与铜死亡相关的长链非编码RNA特征用于预测软组织肉瘤的预后并指示免疫微环境特征
J Oncol. 2022 Jul 6;2022:8489387. doi: 10.1155/2022/8489387. eCollection 2022.
4
Investigating the Potential of Isolating and Expanding Tumour-Infiltrating Lymphocytes from Adult Sarcoma.研究从成人肉瘤中分离和扩增肿瘤浸润淋巴细胞的潜力。
Cancers (Basel). 2022 Jan 21;14(3):548. doi: 10.3390/cancers14030548.
5
Tumor and Peripheral Immune Status in Soft Tissue Sarcoma: Implications for Immunotherapy.软组织肉瘤中的肿瘤与外周免疫状态：对免疫治疗的启示
Cancers (Basel). 2021 Aug 1;13(15):3885. doi: 10.3390/cancers13153885.
6
Multiplex Immunofluorescence Tyramide Signal Amplification for Immune Cell Profiling of Paraffin-Embedded Tumor Tissues.用于石蜡包埋肿瘤组织免疫细胞分析的多重免疫荧光酪胺信号放大技术
Front Mol Biosci. 2021 Apr 29;8:667067. doi: 10.3389/fmolb.2021.667067. eCollection 2021.
7
Predicting the Efficacy and Safety of TACTICs (Tumor Angiogenesis-Specific CAR-T Cells Impacting Cancers) Therapy for Soft Tissue Sarcoma Patients.预测TACTICs（影响癌症的肿瘤血管生成特异性嵌合抗原受体T细胞）疗法对软组织肉瘤患者的疗效和安全性。
Cancers (Basel). 2020 Sep 23;12(10):2735. doi: 10.3390/cancers12102735.
8
MAGE-A3 is a Clinically Relevant Target in Undifferentiated Pleomorphic Sarcoma/Myxofibrosarcoma.黑色素瘤相关抗原A3（MAGE - A3）是未分化多形性肉瘤/黏液纤维肉瘤的一个临床相关靶点。
Cancers (Basel). 2019 May 15;11(5):677. doi: 10.3390/cancers11050677.
9
Positive Tumor Response to Combined Checkpoint Inhibitors in a Patient With Refractory Alveolar Soft Part Sarcoma: A Case Report.一名难治性肺泡软组织肉瘤患者对联合检查点抑制剂产生阳性肿瘤反应：病例报告
J Glob Oncol. 2018 Sep;4:1-6. doi: 10.1200/JGO.2017.009993. Epub 2017 Jul 6.
10
PD-L1 and PD-1 and characterization of tumor-infiltrating lymphocytes in high grade sarcomas of soft tissue - prognostic implications and rationale for immunotherapy.PD-L1、PD-1与高级别软组织肉瘤中肿瘤浸润淋巴细胞的特征——免疫治疗的预后意义及理论依据
Oncoimmunology. 2017 Nov 20;7(3):e1389366. doi: 10.1080/2162402X.2017.1389366. eCollection 2018.
本文引用的文献
1
The immune microenvironment: a major player in human cancers.免疫微环境：人类癌症的主要参与者。
Int Arch Allergy Immunol. 2014;164(1):13-26. doi: 10.1159/000362332. Epub 2014 May 13.
2
Development of a T cell receptor targeting an HLA-A*0201 restricted epitope from the cancer-testis antigen SSX2 for adoptive immunotherapy of cancer.开发一种靶向癌症-睾丸抗原SSX2中HLA-A*0201限制性表位的T细胞受体，用于癌症的过继性免疫治疗。
PLoS One. 2014 Mar 28;9(3):e93321. doi: 10.1371/journal.pone.0093321. eCollection 2014.
3
Systemic treatment of soft-tissue sarcoma-gold standard and novel therapies.软组织肉瘤的系统治疗-金标准和新疗法。
Nat Rev Clin Oncol. 2014 Apr;11(4):187-202. doi: 10.1038/nrclinonc.2014.26. Epub 2014 Mar 18.
4
Cytokine-induced killer cells eradicate bone and soft-tissue sarcomas.细胞因子诱导的杀伤细胞能消灭骨和软组织肉瘤。
Cancer Res. 2014 Jan 1;74(1):119-29. doi: 10.1158/0008-5472.CAN-13-1559. Epub 2013 Dec 19.
5
Tumor infiltrating PD1-positive lymphocytes and the expression of PD-L1 predict poor prognosis of soft tissue sarcomas.肿瘤浸润性PD1阳性淋巴细胞及PD-L1的表达预示软组织肉瘤预后不良。
PLoS One. 2013 Dec 11;8(12):e82870. doi: 10.1371/journal.pone.0082870. eCollection 2013.
6
The use of endogenous T cells for adoptive transfer.内源性 T 细胞的过继转移。
Immunol Rev. 2014 Jan;257(1):250-63. doi: 10.1111/imr.12134.
7
CD8⁺ tumor-infiltrating lymphocytes at primary sites as a possible prognostic factor of cutaneous angiosarcoma.原发部位 CD8⁺ 肿瘤浸润淋巴细胞或可作为皮肤血管肉瘤的预后因素。
Int J Cancer. 2014 May 15;134(10):2393-402. doi: 10.1002/ijc.28581. Epub 2013 Nov 18.
8
Novel systemic therapies in advanced liposarcoma: a review of recent clinical trial results.新型系统疗法在晚期脂肪肉瘤中的应用：对近期临床试验结果的回顾。
Cancers (Basel). 2013 May 10;5(2):529-49. doi: 10.3390/cancers5020529.
9
Phase II study of personalized peptide vaccination for refractory bone and soft tissue sarcoma patients.个体化肽疫苗治疗难治性骨和软组织肉瘤患者的 II 期研究。
Cancer Sci. 2013 Oct;104(10):1285-94. doi: 10.1111/cas.12226. Epub 2013 Aug 6.
10
Mutational heterogeneity in cancer and the search for new cancer-associated genes.癌症中的突变异质性与新的癌症相关基因的寻找。
Nature. 2013 Jul 11;499(7457):214-218. doi: 10.1038/nature12213. Epub 2013 Jun 16.
Zotero 插件